Neurology

Editors' note: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology


In “Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology,” Rae-Grant et al. provided recommendations for use of disease-modifying therapy in patients with multiple sclerosis. Dr. Saltonstall, for Sanofi Genzyme, identified the following 3 concerns regarding teriflunomide in the recommendations: (1) characterization of teriflunomide as being transmitted in sperm and intercalating with DNA leading to teratogenicity unless treatment with chelation therapy is administered; (2) notation that teriflunomide should be switched to another agent if a person develops malignancy; and (3) indication that teriflunomide data are not Class I evidence.

Source link

Related posts

To Bust Stress, Turn Your Attention To The Positive

Newsemia

Science Daily: ‘Lack of cleaning’ in brain cells is central to Alzheimer’s disease

Newsemia

Why Getting “Brainwashed” Is A Good Thing

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World